Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of motesanib plus paclitaxel + carboplatin in advanced non-squamous non-small cell lung cancer (Asian study)
jRCT2080221842Phase 3
- Sponsor
- Takeda
- Start
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Non-small cell lung cancer (NS-NSCLC) comparing Motesanib + paclitaxel + carboplatin with Placebo + paclitaxel + carboplatin (2 arms).
02
Drugs
motesanib
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on jRCT2080221842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221842.